Abstract
BackgroundProtease-Activated Receptor-1 (PAR-1) plays an important role in the pathogenesis of multiple malignancies and its expression strongly also affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of PAR-1in cutaneous melanoma patients. MethodsA total of 60 patients with a pathologically confirmed diagnosis of cutaneous melanoma were enrolled into this study. Serum PAR-1concentrations were determined by the solid-phase sandwich ELISA method. ResultsNo significant difference in serum PAR-1 levels between melanoma patients and healthy controls was found (p=0.07). The known clinical variables including age of patient, gender, site of lesion, histology, stage of disease, serum LDH levels and chemotherapy responsiveness were not correlated with serum PAR-1 concentrations (p>0.05). Likewise, serum PAR-1 concentration had also no prognostic role on survival (p=0.41). ConclusionSerum levels of PAR-1 have no diagnostic, predictive and prognostic roles in cutaneous melanoma patients. General significanceMeasurement of PAR-1 in serum is not a clinical significance in cutaneous melanoma patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
